Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,003.00-1.37%ETH$2,254.70-0.65%GOLD$3,963.20-0.16%OIL$96.91+0.47%
Smart Investors Daily
SID Premium
IO

NASDAQ · IOVA

Iovance Biotherapeutics, Inc.

Healthcare · Biotechnology

$8.48

Down-$0.46 (-5.42%)

Updated Nov 3, 2026, 12:56 AM

SID Score

5.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
744.64M
P/E ratio
-1.93
Dividend yield
0.00%
52-week range
$1.76 – $15.37
Volume
31.2M
Avg. volume
13.69M

Price performance · IOVA

IOVA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

IOVA closed at $8.48 after 20 trading sessions, down 40.07% for the selected period.

Last close
$8.48
Period change
-40.07%
Period low
$8.48
Period high
$14.86
Daily close
View OHLC price history
IOVA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$9.125$9.17$8.265$8.4831.2M
Oct 29, 2026$10.70$11.58$9.345$9.5659.23M
Oct 28, 2026$14.30$14.91$14.18$14.819.71M
Oct 27, 2026$13.74$14.78$13.59$14.588.8M
Oct 26, 2026$14.20$14.20$13.3234$13.787.44M
Oct 23, 2026$14.185$14.30$13.54$14.097.76M
Oct 22, 2026$14.405$14.6984$13.64$14.1410.77M
Oct 21, 2026$14.945$15.37$14.59$14.6211.01M
Oct 20, 2026$14.18$14.955$13.83$14.869.75M
Oct 19, 2026$13.80$14.74$13.78$14.218.51M
Oct 16, 2026$14.65$14.71$13.515$13.6212.19M
Oct 15, 2026$14.01$14.74$13.8047$14.7211.52M
Oct 14, 2026$14.35$14.64$14.15$14.2110.63M
Oct 13, 2026$14.483$14.80$14.31$14.5011.92M
Oct 12, 2026$14.50$14.82$14.20$14.569.11M
Oct 9, 2026$13.36$14.94$13.29$14.6216.99M
Oct 8, 2026$12.645$13.395$12.62$13.3114.82M
Oct 7, 2026$12.515$13.148$12.31$12.91514.53M
Oct 6, 2026$14.21$14.21$12.92$12.9618.95M
Oct 5, 2026$14.03$14.405$13.71$14.1511.75M

Latest IOVA news

The latest Smart Investors Daily articles mentioning IOVA.

Stock researchCompany · Overview

IOVA research

Overview

Company profile and research snapshot.

Company profile

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$14.25
Implied upside
—
Analysts
—
IOVA recent ratings
DateFirmRatingTarget
Oct 13, 2026BarclaysOverweight—
Oct 8, 2026BairdNeutral—
Sep 30, 2026Wells FargoOverweight—
Sep 29, 2026HC Wainwright & Co.Buy—
Sep 24, 2026Goldman SachsBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026

PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, November 5, 2026 at 8:30 a.m. ET to report its third quarter 2026 financial results and corporate updates. To listen to the live or archived audio webcast, please regis

Yahoo · Oct 26, 2026

Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Unprecedented Efficacy in Both Refractory Undifferentiated Pleomorphic Sarcoma (UPS) and Dedifferentiated Liposarcoma (DDLPS) PHILADELPHIA and MADRID, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor

Yahoo · Oct 23, 2026

Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma

62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 Analysis Median Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-up Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 Reinforces Ongoing TILVANCE-301 Phase 3 Trial PHILADELPHIA and MADRID, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By